Metastatic colon cancer: clinical practice guideline update in 2024

This article presents changes to clinical guidelines for the treatment of metastatic colon cancer in 2024. The new provisions in the clinical guidelines are complemented by a brief overview of the research results that underlie them. The changes considered concern not only systemic antitumor treatment, but also surgery and molecular genetic diagnostics. The differences between the recommendations of RUSSCO and the Ministry of Health of Russia are given. The introduction of information to determine the clinical benefit of expensive therapeutic options in relation to the use of the ESMO-MCBS and RUSSCO-MCBS scales is discussed.Aim. Bringing information to a wide range of readers on planned changes in clinical guidelines.

Authors

Institutions

Publication Details

Journal
Surgery and Oncology
Published
2024-11-29
DOI
https://doi.org/10.17650/2949-5857-2024-14-4-31-42
Citations
2
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metastatic colon cancer: clinical practice guideline update in 2024

I. V. Rykov, S. S. Gordeyev, З. З. Мамедли, М. В. Черных et al.
2 citations
Surgery and Oncology
Colorectal Cancer Treatments and Studies
0.57
article

Metastatic colon cancer: clinical practice guideline update in 2024

I. V. Rykov, S. S. Gordeyev, З. З. Мамедли, М. В. Черных, Н. А. Козлов, A. Tryakin, А. М. Карачун, O. A. Gladkov, М. Yu. Fedyanin, А. С. Цуканов
article en
2 citations

Abstract

This article presents changes to clinical guidelines for the treatment of metastatic colon cancer in 2024. The new provisions in the clinical guidelines are complemented by a brief overview of the research results that underlie them. The changes considered concern not only systemic antitumor treatment, but also surgery and molecular genetic diagnostics. The differences between the recommendations of RUSSCO and the Ministry of Health of Russia are given. The introduction of information to determine the clinical benefit of expensive therapeutic options in relation to the use of the ESMO-MCBS and RUSSCO-MCBS scales is discussed.Aim. Bringing information to a wide range of readers on planned changes in clinical guidelines.

Surgery and OncologyVol. 14(4)
Sechenov University (RU), Federal Almazov North-West Medical Research Centre (RU), Moscow Clinical Scientific Center (RU), State Scientific Center of Coloproctology (RU), Unimed Medical Institute (CN), National Medical and Surgical Center named after N.I. Pirogov (RU), Ministry of Health of the Russian Federation (RU), Chelyabinsk Regional Clinical Oncology Center (RU), North-Western State Medical University named after I.I. Mechnikov (RU), Tyumen State Medical University (RU)
Good health and well-being
Openalex Percentile: Top 26%
Colorectal Cancer Treatments and Studies
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.